Analytical Validation and Stability Indicating Studies for Simultaneous Estimation of Serdexmethylphenidate and Dexmethylphenidate by RP-HPLC in Bulk and Capsules

Abstract

A stability-indicating RP-HPLC method for the simultaneous determination of Serdexmethylphenidate (SER) and Dexmethylphenidate (DEX) has been developed and validated in bulk and tablet dosage forms. SER and DEX are central nervous system stimulants. This combination is used to treat attention deficit hyperactive disorder. The chromatographic analysis was carried out on a Waters C18 Column with 250mm x 4.6 and a particle size of 5 μm, using an isocratic mobile phase of Phosphate Buffer pH 4.8: Methanol (70:30, v/v) at a flow rate of 0.8 mL/min, and the eluents were monitored at an isosbestic point of 215 nm. Specificity, precision, accuracy, linearity, and robustness of the proposed method were all validated according to ICH standards. Forced degradation studies confirmed the method's stability indicating nature. SER and DEX had retention times of 2.390 and 4.602 min, respectively. The developed technique was found to be specific and accurate. SER linearity was achieved between 90-270 μg/mL, while DEX linearity was obtained between 17.50-52.50 μg/mL. SER had LOD and LOQ of 6.35 and 21.17 μg/mL, whereas DEX had LOD and LOQ of 1.18 and 3.93 μg/mL, respectively. As a result, the suggested HPLC method for the quantification of Serdexmethylphenidate (SER) and Dexmethylphenidate (DEX) was reliable, repeatable, accurate, and sensitive.